Europe Fertility Supplements Market Size, Share & Industry Trends Analysis Report By Ingredient, By End-Use (Women and Men), By Distribution Channel, By Product (Capsules, Tablets, Soft Gels, Powder, and Liquid), By Country and Growth Forecast, 2022 - 2028

The Europe Fertility Supplements Market should witness market growth of 6.7% CAGR during the forecast period (2022-2028).

A lot of studies have been done on the relationship between micronutrients and fertility to recognize the usage of each type of supplement on a particular being. This is because every person is unique and might react differently to micronutrients affecting fertility. Many advancements and research have boosted customer requirements for fertility supplements. Certain studies found that in a significant percentage of infertile couples, solely the male component was discovered to be infertile.

Poor sperm counts or decreased sperm motility which may be brought on by hormonal abnormalities are the most commonly recognized causes of male infertility. Infertility in women can result from a variety of conditions that affect the ovaries, fallopian tubes, uterus, endocrine system, and many others. People can have either primary or secondary infertility. A person has secondary infertility if at least one previous pregnancy has been accomplished, while primary infertility occurs when a conception has not been achieved.

The prevalence of obesity and the growing number of people with diabetes in Germany are increasing the need for fertility supplements. In obese women, anovulation and menstrual problems are more prevalent. Women who are fat or overweight have an increased chance of miscarrying. These women are more likely to experience sub-fecundity, and infertility, in addition to increased rates of miscarriage, conception, and pregnancy complications; as a result, the nation consumes more of the product.

The Germany market dominated the Europe Fertility Supplements Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $175.1 million by 2028. The UK market is estimated to grow a CAGR of 5.8% during (2022-2028). Additionally, The France market would experience a CAGR of 7.5% during (2022-2028).

Based on Ingredient, the market is segmented into Synthetic/ Blend of Natural & Synthetic and Natural. Based on End-Use, the market is segmented into Women and Men. Based on Distribution Channel, the market is segmented into Over-the-counter and Prescribed. Based on Product, the market is segmented into Capsules, Tablets, Soft Gels, Powder, and Liquid. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Fairhaven Health, Coast Science LLC, LENUS Pharma GesmbH, CellOxess LLC, Orthomol pharmazeutische Vertriebs GmbH, Exeltis USA, Inc. (Grupo INSUD), Yad-Tech, Bionova Lifesciences (Pragati Biocare Pvt. Ltd.), Vitabiotics Ltd., and TTK Healthcare Limited.

Scope of the Study

By Ingredient

• Synthetic/ Blend of Natural & Synthetic
• Natural

By End-use

• Women
• Men

By Distribution Channel

• Over-the-counter
• Prescribed

By Product

• Capsules
• Tablets
• Soft Gels
• Powder
• Liquid

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Fairhaven Health
• Coast Science LLC
• LENUS Pharma GesmbH
• CellOxess LLC
• Orthomol pharmazeutische Vertriebs GmbH
• Exeltis USA, Inc. (Grupo INSUD)
• Yad-Tech
• Bionova Lifesciences (Pragati Biocare Pvt. Ltd.)
• Vitabiotics Ltd.
• TTK Healthcare Limited

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free